Newsroom

 Glenmark appoints Dipankar Bhattacharjee to its Board of Directors

17 Aug 2020 | Read More

Glenmark’s consolidated revenue grew by 0.94 % at Rs. 23,447.87 Mn. for Q1 FY 2020-21

14 Aug 2020 | Read More

Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce pill burden of COVID-19 treatment

6 Aug 2020 | Read More

Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19

22 Jul 2020 | Read More

Glenmark launches world's first Hypertension Awareness symbol, endorsed by Association of Physicians of India (API) & Hypertension Society of India (HSI)

20 Jul 2020 | Read More

Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®

13 Jul 2020 | Read More

Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY2019-20

26 Jun 2020 | Read More

Glenmark introduces Favipiravir (FabiFlu®) for the treatment of mild to moderate COVID-19 in India

22 Jun 2020 | Read More

Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19

20 Jun 2020 | Read More

Indian regulator approves Favipiravir for the treatment of mild to moderate COVID-19 in India

19 Jun 2020 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Fingolimod Capsules, 0.5 mg

19 Jun 2020 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Chlorzoxazone Tablets USP, 375 mg and 750 mg; Glenmark’s first ANDA approval out of their new U.S. facility

27 May 2020 | Read More

Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India

26 May 2020 | Read More

Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

12 May 2020 | Read More

Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function

11 May 2020 | Read More

Glenmark receives approval from the regulator (DCGI) to conduct Clinical Trials in India on Favipiravir Antiviral tablets for COVID-19 patients

30 Apr 2020 | Read More

Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg

29 Apr 2020 | Read More

Glenmark pledges 50 lakh meals for undernourished children, pregnant women and daily wage earners amidst COVID-19 pandemic

22 Apr 2020 | Read More

Glenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever

23 Mar 2020 | Read More

 Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg

23 Mar 2020 | Read More

Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US

27 Feb 2020 | Read More

Glenmark’s consolidated revenue rises by 7.07% to Rs. 27,355.61 Mn. in Q3 FY 2019-20

14 Feb 2020 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg

7 Jan 2020 | Read More

Library

Profile – Chairman and Managing Director
+
Profile – Chairman and Managing Director
With the idea of creating something unique, Glenn Saldanha took over the reins of the company and helped transform it into a global enterprise worth USD 1.4 billion with offices across 40 countries. Download Profile
Profile – Glenmark Pharmaceuticals
+
Profile – Glenmark Pharmaceuticals
Research-driven, global and integrated pharmaceutical company which is driven to meet unmet medical needs and help pave a new way for a new world. Download Profile

For any media related queries, please email corpcomm@glenmarkpharma.com